Tags

Type your tag names separated by a space and hit enter

Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial.
JAMA. 2012 Nov 14; 308(18):1871-80.JAMA

Abstract

CONTEXT

Multivitamin preparations are the most common dietary supplement, taken by at least one-third of all US adults. Observational studies have not provided evidence regarding associations of multivitamin use with total and site-specific cancer incidence or mortality.

OBJECTIVE

To determine whether long-term multivitamin supplementation decreases the risk of total and site-specific cancer events among men.

DESIGN, SETTING, AND PARTICIPANTS

A large-scale, randomized, double-blind, placebo controlled trial (Physicians" Health Study II) of 14 641 male US physicians initially aged 50 years or older (mean [SD] age, 64.3 [9.2] years), including 1312 men with a history of cancer at randomization, enrolled in a common multivitamin study that began in 1997 with treatment and follow-up through June 1, 2011.

INTERVENTION

Daily multivitamin or placebo.

MAIN OUTCOME MEASURES

Total cancer (excluding nonmelanoma skin cancer), with prostate, colorectal, and other site-specific cancers among the secondary end points.

RESULTS

During a median (interquartile range) follow-up of 11.2 (10.7-13.3) years, there were 2669 men with confirmed cancer, including 1373 cases of prostate cancer and 210 cases of colorectal cancer. Compared with placebo, men taking a daily multivitamin had a statistically significant reduction in the incidence of total cancer (multivitamin and placebo groups, 17.0 and 18.3 events, respectively, per 1000 person-years; hazard ratio [HR], 0.92; 95% CI, 0.86-0.998; P=.04). There was no significant effect of a daily multivitamin on prostate cancer (multivitamin and placebo groups, 9.1 and 9.2 events, respectively, per 1000 person-years; HR, 0.98; 95% CI, 0.88-1.09; P=.76), colorectal cancer (multivitamin and placebo groups, 1.2 and 1.4 events, respectively, per 1000 person-years; HR, 0.89; 95% CI, 0.68-1.17; P=.39), or other site-specific cancers. There was no significant difference in the risk of cancer mortality (multivitamin and placebo groups, 4.9 and 5.6 events, respectively, per 1000 person-years; HR, 0.88; 95% CI, 0.77-1.01; P=.07). Daily multivitamin use was associated with a reduction in total cancer among 1312 men with a baseline history of cancer (HR, 0.73; 95% CI, 0.56-0.96; P=.02), but this did not differ significantly from that among 13 329 men initially without cancer (HR, 0.94; 95% CI, 0.87-1.02; P=.15; P for interaction=.07). Conclusion In this large prevention trial of male physicians, daily multivitamin supplementation modestly but significantly reduced the risk of total cancer.

TRIAL REGISTRATION

clinicaltrials.gov Identifier: NCT00270647.

Authors+Show Affiliations

Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts 02120, USA. jmgaziano@partners.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23162860

Citation

Gaziano, J Michael, et al. "Multivitamins in the Prevention of Cancer in Men: the Physicians' Health Study II Randomized Controlled Trial." JAMA, vol. 308, no. 18, 2012, pp. 1871-80.
Gaziano JM, Sesso HD, Christen WG, et al. Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA. 2012;308(18):1871-80.
Gaziano, J. M., Sesso, H. D., Christen, W. G., Bubes, V., Smith, J. P., MacFadyen, J., Schvartz, M., Manson, J. E., Glynn, R. J., & Buring, J. E. (2012). Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA, 308(18), 1871-80.
Gaziano JM, et al. Multivitamins in the Prevention of Cancer in Men: the Physicians' Health Study II Randomized Controlled Trial. JAMA. 2012 Nov 14;308(18):1871-80. PubMed PMID: 23162860.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. AU - Gaziano,J Michael, AU - Sesso,Howard D, AU - Christen,William G, AU - Bubes,Vadim, AU - Smith,Joanne P, AU - MacFadyen,Jean, AU - Schvartz,Miriam, AU - Manson,JoAnn E, AU - Glynn,Robert J, AU - Buring,Julie E, PY - 2012/11/20/entrez PY - 2012/11/20/pubmed PY - 2012/12/10/medline SP - 1871 EP - 80 JF - JAMA JO - JAMA VL - 308 IS - 18 N2 - CONTEXT: Multivitamin preparations are the most common dietary supplement, taken by at least one-third of all US adults. Observational studies have not provided evidence regarding associations of multivitamin use with total and site-specific cancer incidence or mortality. OBJECTIVE: To determine whether long-term multivitamin supplementation decreases the risk of total and site-specific cancer events among men. DESIGN, SETTING, AND PARTICIPANTS: A large-scale, randomized, double-blind, placebo controlled trial (Physicians" Health Study II) of 14 641 male US physicians initially aged 50 years or older (mean [SD] age, 64.3 [9.2] years), including 1312 men with a history of cancer at randomization, enrolled in a common multivitamin study that began in 1997 with treatment and follow-up through June 1, 2011. INTERVENTION: Daily multivitamin or placebo. MAIN OUTCOME MEASURES: Total cancer (excluding nonmelanoma skin cancer), with prostate, colorectal, and other site-specific cancers among the secondary end points. RESULTS: During a median (interquartile range) follow-up of 11.2 (10.7-13.3) years, there were 2669 men with confirmed cancer, including 1373 cases of prostate cancer and 210 cases of colorectal cancer. Compared with placebo, men taking a daily multivitamin had a statistically significant reduction in the incidence of total cancer (multivitamin and placebo groups, 17.0 and 18.3 events, respectively, per 1000 person-years; hazard ratio [HR], 0.92; 95% CI, 0.86-0.998; P=.04). There was no significant effect of a daily multivitamin on prostate cancer (multivitamin and placebo groups, 9.1 and 9.2 events, respectively, per 1000 person-years; HR, 0.98; 95% CI, 0.88-1.09; P=.76), colorectal cancer (multivitamin and placebo groups, 1.2 and 1.4 events, respectively, per 1000 person-years; HR, 0.89; 95% CI, 0.68-1.17; P=.39), or other site-specific cancers. There was no significant difference in the risk of cancer mortality (multivitamin and placebo groups, 4.9 and 5.6 events, respectively, per 1000 person-years; HR, 0.88; 95% CI, 0.77-1.01; P=.07). Daily multivitamin use was associated with a reduction in total cancer among 1312 men with a baseline history of cancer (HR, 0.73; 95% CI, 0.56-0.96; P=.02), but this did not differ significantly from that among 13 329 men initially without cancer (HR, 0.94; 95% CI, 0.87-1.02; P=.15; P for interaction=.07). Conclusion In this large prevention trial of male physicians, daily multivitamin supplementation modestly but significantly reduced the risk of total cancer. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00270647. SN - 1538-3598 UR - https://www.unboundmedicine.com/medline/citation/23162860/Multivitamins_in_the_prevention_of_cancer_in_men:_the_Physicians'_Health_Study_II_randomized_controlled_trial_ L2 - https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2012.14641 DB - PRIME DP - Unbound Medicine ER -